AstraZeneca Plc, the U.K.’s second- biggest drugmaker, is advancing experimental drugs into late- stage clinical trials faster than expected in a bid to replace sales that it’s losing to generic competitors.
Sanofi’s multiple sclerosis drug Lemtrada is effective for preventing flare-ups of the disease, U.S. regulatory advisers said yesterday, even as they decided the company’s trials weren’t adequate to assess the drug.
GlaxoSmithKline Plc will stop paying doctors to promote its medicines amid Chinese government accusations that the U.K. drugmaker bribed physicians, a year after the company admitted to marketing offenses in the U.S.
GlaxoSmithKline Plc’s sales in China jumped 20 percent to about 1 billion pounds ($1.5 billion) last year, almost quadruple the pace of growth across its emerging markets. Police say bribes and sexual favors spurred the gain.